Acute Myeloid Leukemia Clinical Trial
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
Summary
This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
Full Description
PRIMARY OBJECTIVE:
I. To evaluate immune profile of AML patients receiving venetoclax plus azacitidine induction chemotherapy.
SECONDARY OBJECTIVE:
I. To determine clinical responses based on immune infiltrated vs immune depleted subtypes of AML receiving azacitidine and venetoclax chemotherapy.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and bone marrow aspirate on study. Patients' medical records are reviewed.
Eligibility Criteria
Inclusion Criteria:
Adults > 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy
Treatment naive adult acute myeloid leukemia patients
Exclusion Criteria:
Acute myeloid leukemia patients receiving azacitidine and venetoclax as salvage therapy will be excluded
Patients who are pregnant or breast-feeding
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Scottsdale Arizona, 85259, United States More Info
Principal Investigator
Jacksonville Florida, 32224, United States More Info
Principal Investigator
Rochester Minnesota, 55905, United States More Info
Principal Investigator
How clear is this clinincal trial information?